CCRA Certified Clinical Research Study 3 — Questions and Answers
Question 1: During a routine monitoring visit, the CRA notices the investigational product (IP) storage temperature log shows a 4-hour excursion outside the specified range. What is the MOST appropriate next step?
- Quarantine the affected IP and notify the sponsor for disposition instructions (Correct answer)
- Continue using the IP since a short excursion is unlikely to affect quality
- Discard the IP immediately without sponsor consultation
- Document the excursion and take no further action
Correct answer: Quarantine the affected IP and notify the sponsor for disposition instructions
Affected IP must be quarantined pending sponsor assessment; only the sponsor/manufacturer can determine whether the product remains usable.
Question 2: Which element is NOT required to be included in an informed consent form according to 21 CFR Part 50.25?
- A statement that participation is voluntary
- The expected duration of the subject's participation
- The subject's social security number (Correct answer)
- A description of foreseeable risks or discomforts
Correct answer: The subject's social security number
21 CFR 50.25 lists required ICF elements, and a subject's social security number is not among them; collecting it would be a privacy concern.
Question 3: A sponsor's risk-based monitoring plan categorizes Site A as 'high risk.' Which combination of factors most likely triggered this designation?
- High enrollment rate and experienced staff
- New site, high enrollment rate, and multiple protocol deviations (Correct answer)
- Low enrollment rate and minimal adverse events
- Experienced PI and no prior deviations
Correct answer: New site, high enrollment rate, and multiple protocol deviations
Risk-based monitoring assigns higher risk to sites with inexperience, rapid enrollment, and a history of deviations — indicators of increased error probability.
Question 4: Under GCP, what does the term 'blinding/masking' refer to in the context of a randomized controlled trial?
- Concealing the study protocol from regulators
- Preventing one or more parties from knowing the treatment assignment (Correct answer)
- Destroying unneeded study documents after trial completion
- Restricting subject access to their own medical records
Correct answer: Preventing one or more parties from knowing the treatment assignment
Blinding prevents knowledge of treatment assignment by subjects, investigators, or both to reduce bias in a randomized controlled trial.
Question 5: When must a protocol deviation be reported to the IRB according to standard GCP practice?
- All deviations must be reported within 24 hours
- Only deviations that affect subject safety or data integrity require IRB reporting per IRB SOPs (Correct answer)
- Deviations are only reported at study close-out
- Deviations are never reported to the IRB, only to the sponsor
Correct answer: Only deviations that affect subject safety or data integrity require IRB reporting per IRB SOPs
IRB reporting requirements vary by institution, but deviations that affect subject safety, rights, or data integrity generally require prompt IRB notification per site SOPs.
Question 6: What is the primary purpose of the Declaration of Helsinki?
- To establish FDA regulatory requirements for drug approval
- To provide ethical principles for medical research involving human subjects (Correct answer)
- To set standards for statistical analysis in clinical trials
- To define Good Manufacturing Practice (GMP) requirements
Correct answer: To provide ethical principles for medical research involving human subjects
The Declaration of Helsinki is a foundational ethical document developed by the World Medical Association to guide researchers conducting studies involving human participants.
Question 7: A CRA notices that a site coordinator has been signing consent forms as the 'person obtaining consent' without being listed on the site's delegation of authority log. What is this an example of?
- A minor protocol deviation with no impact
- An unauthorized activity constituting a GCP violation (Correct answer)
- Standard practice at community research sites
- An acceptable exception if the PI later countersigns
Correct answer: An unauthorized activity constituting a GCP violation
All personnel performing delegated trial tasks must be listed on the delegation of authority log; undocumented delegation is a GCP violation regardless of subsequent countersignature.
CCRA Certified Clinical Research Study 3
During a routine monitoring visit, the CRA notices the investigational product (IP) storage temperature log shows a 4-hour excursion outside the specified range.
What is the MOST appropriate next step?